Back

Micromagnetic Stimulation (μMS) Controls Dopamine Release: An in vivo Study Using WINCS Harmoni

Saha, R.; Goyal, A.; Yuen, J.; Oh, Y.; Bloom, R. P.; Benally, O. J.; Wu, K.; Netoff, T. I.; Low, W. C.; Bennet, K. E.; Lee, K. H.; Wang, J.-P.

2023-05-25 neuroscience
10.1101/2023.05.25.542334 bioRxiv
Show abstract

ObjectiveResearch into the role of neurotransmitters in regulating normal and pathologic brain functions has made significant progress. Yet, clinical trials that aim to improve therapeutic interventions do not take advantage of the in vivo changes in the neurochemistry that occur in real time during disease progression, drug interactions or response to pharmacological, cognitive, behavioral, and neuromodulation therapies. In this work, we used the WINCS Harmoni tool to study the real time in vivo changes in dopamine release in rodent brains for the micromagnetic neuromodulation therapy. ApproachAlthough still in its infancy, micromagnetic stimulation (MS) using micro-meter sized coils or microcoils (coils) has shown incredible promise in spatially selective, galvanic contact free and highly focal neuromodulation. These coils are powered by a time-varying current which generates a magnetic field. As per Faradays Laws of Electromagnetic Induction, this magnetic field induces an electric field in a conducting medium (here, the brain tissues). We used a solenoidal-shaped coil to stimulate the medial forebrain bundle (MFB) of the rodent brain in vivo. The evoked in vivo dopamine releases in the striatum were tracked in real time by carbon fiber microelectrodes (CFM) using fast scan cyclic voltammetry (FSCV). ResultsOur experiments report that coils can successfully activate the MFB in rodent brains, triggering dopamine release in vivo. We further show that the successful release of dopamine upon micromagnetic stimulation is dependent on the orientation of the coil. Furthermore, varied intensities of MS can control the concentration of dopamine releases in the striatum. SignificanceThis work helps us better understand the brain and its conditions arising from a new therapeutic intervention, like MS, at the level of neurotransmitter release. Despite its early stage, this study potentially paves the path for MS to enter the clinical world as a precisely controlled and optimized neuromodulation therapy.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.